IL12B gene (rs6887695) genotype GG and (rs3213094) genotype CC are more frequently observed in psoriatic patients

Abstract

Introduction & objectives: Psoriasis is a chronic inflammatory multifactorial disease having the genetic background. IL12 and IL23 are the most frequent cytokines involved into the immunological process leading to psoriasis. The purpose of our study was to assess the link between IL12B and IL23R gene polymorphisms and psoriasis. Objectives of the study were formulated as follows: 1) to investigate the frequency of gene polymorphism in patients with psoriasis and healthy subjects genotypes and 2) to determine, whether there is a statistically significant correlation between the genotype and psoriasis. Material & methods: A number of 100 psoriatic patients and 304 healthy people (control group) were tested. Genomic deoxyribonucleic acid (DNA) was extracted by salting out procedure from peripheral blood leukocytes and the genotyping was accomplished by real-time PCR method using comercially available TaqMan probes for IL12B and IL23R gene polymorphisms. For the univariate analysis of nominal variables the Pearson Chi-Square Test, the Fisher’s Exact Test were used. The chi-squared test was used to assess the Hardy–Weinberg equilibrium. Results: Allelic frequencies of C allele (rs3213094), G allele of IL12B gene (rs6887695) and A allele of IL23R gene (rs2201841) were estimated to be as follow in patient group: 84% (95% CI 78.9-89.1), 84% (95% CI: 78.9-89.1) and 78% (95% CI: 72.3-83.7) respectively. Allelic frequencies in control group: C allele (rs3213094), G allele (rs6887695) of IL12B gene and A allele of IL23R gene (rs2201841) were 81% (95% CI: 77.9-84.1), 76% (95% CI: 72.6-79.4) and 71% (95% CI: 67.4-74.6). The allelic frequencies of T allele (rs3213094), C allele (rs6887695) of IL12B gene and G allele (rs2201841) of IL23R gene were 16% (95% CI: 10.4-21.1), 16% (95% CI: 10.9-21.1) and 22% (95% CI: 16.3-27.7) in patient group and 19% (95% CI: 13.6-24.4), 24% (95% CI: 18.1-29.9) and 29% (95% CI: 22.7-35.3) . [...].